TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07178431: An Open Label Phase I/IIa, Multicenter, Interventional Single-arm Trial of MB-CART 2019.1 in Patients With Refractory Multiple Sclerosis (MS)

Sponsor: Miltenyi Biomedicine GmbH · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 26 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07178431 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07178431 Rescue Dossier →